Skip to main content

Table 5 RAND SF-36 changes in scores

From: Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis

 

Baseline to 1 month (N = 20)

Baseline to 1 year (N = 17)

Better

Same

Worse

Better

Same

Worse

Physical functioning

7 (35%)

4 (20%)

9 (45%)

10 (59%)

1 (6%)

6 (35%)

Role limitations—physicala

13 (65%)

6 (30%)

1 (5%)

11 (65%)

4 (24%)

2 (12%)

Role limitations—emotional

7 (35%)

10 (50%)

3 (15%)

5 (29%)

9 (53%)

3 (18%)

Energy/fatigueb

16 (80%)

1 (5%)

3 (15%)

11 (65%)

0 (0%)

6 (35%)

Emotional well-being

13 (65%)

2 (10%)

5 (25%)

10 (59%)

2 (12%)

5 (29%)

Social functioning

12 (60%)

2 (10%)

6 (30%)

8 (47%)

1 (6%)

8 (47%)

Pain

9 (45%)

5 (25%)

6 (30%)

6 (35%)

8 (47%)

3 (18%)

General health

11 (55%)

1 (5%)

8 (40%)

9 (53%)

2 (12%)

6 (35%)

Health changea

13 (65%)

6 (30%)

1 (5%)

11 (65%)

4 (24%)

2 (12%)

  1. aDifferences between baseline and 1-month and 1-year scores statistically significant (p < 0.03)
  2. bDifferences between baseline and 1-month scores statistically significant (p < 0.001)